Table 1.
Clinical characteristics of the patients after HSCT with PT
| Characteristics | PT cases (n = 34) | Controls (n = 26) | P valuea |
|---|---|---|---|
| Time of evaluation (post-HSCT) | 100 (80–150) | 121 (87–149) | .078 |
| Age at HSCT, median (range), year | 27 (11–56) | 26 (3–58) | .959 |
| Gender (male/female) | 22/12 | 15/11 | .603 |
| PLT count (×109/L) | 33.68 (12–83) | 143.38 (100–219) | <.001 |
| Disease type | |||
| Acute Leukemia | 20 | 14 | .095 |
| Other | 21 | 5 | |
| Source of stem cell | |||
| BM and PB | 29 | 25 | .221 |
| PB | 5 | 1 | |
| Transplanted total nucleated cell dose, ×108/kg | 7.195 (5.00–10.10) | 6.905 (3.44–9.12) | .350 |
| Transplanted CD34+ cells, ×106/kg | 1.925 (0.73–7.42) | 2.465 (0.38–4.47) | .685 |
| Donor type | |||
| HLA partially matched related donor | 26 | 19 | .689 |
| Unrelated donor | 2 | 1 | |
| Identical sibling | 6 | 6 | |
| Status at HSCT | |||
| Standard risk | 26 | 20 | .999 |
| High risk | 8 | 6 | |
| Conditioning regimen | |||
| BU/CY + ATG | 27 | 19 | .239 |
| BU/CY | 4 | 7 | |
| TBI | 3 | 0 | |
| History of severe GvHD | 21 | 8 | .021 |
| History of CMV reactivation | 26 | 12 | .029 |
aThe continuous variables were compared using the one-way ANOVA, and the differences in frequency between the two groups were compared using the Chi-square test